Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Hematology"
DOI: 10.1007/s12185-022-03320-0
Abstract: The glycoengineered, humanized anti-CD20 antibody obinutuzumab is indicated for previously untreated or relapsed/refractory CD20-positive follicular lymphoma (FL). However, the effectiveness of obinutuzumab retreatment in relapsed/refractory FL after prior obinutuzumab-containing therapy is unclear. To address this… read more here.
Keywords: obinutuzumab resistant; antitumor activity; day; resistant tumors ... See more keywords
Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
Sign Up to like & getrecommendations! Published in 2018 at "Oncoimmunology"
DOI: 10.1080/2162402x.2018.1428158
Abstract: ABSTRACT Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is… read more here.
Keywords: anti cd20; lymphocytic leukemia; cd20 antibodies; leukemia cll ... See more keywords